HLA matched lines

Our proprietary HLA-matched CTL and Tumors compliment and confirm data obtained from allogenic studies by validating function and mechanism of drug candidates. These lines are well characterized and suitable for any platform.

Visit our Schedule or Build-a-System to request a study.

CTL and Tumor 001 was derived from a colon cancer patient (Caucasian female). Patient underwent resection of a primary cecal adenocarcinoma, stage Dukes’ B.

CTL and Tumor 002 derived from a female colon cancer patient at time of surgery. The patient received a combination of chemotherapy and radiation for a continuous period of 2 years, starting 1 month after surgery, and succumbed to the disease 4 months after therapy as ended. Cell line is characterized under optimal expansion conditions. Patients’ haplotype is listed as HLA-A1, -A3, —B35, DR.

 

CTL and Tumor 003 derived from a melanoma male Caucasian patient. Tumor excised from a “low risk” melanoma lesion with brisk lymphatic infiltration. No evidence of metastases. Tumor 003 did not receive any chemotherapy after the removal of the primary lesion.

TIL and Tumor 004 derived from a Stage 4 melanoma patient (male). Patient was on Keytruda (anti-PD-1) from November 2015 until July 2016. Removed due to non-responsiveness to Keytruda. Cell line is characterized under optimized expansion conditions.

Fresh Cells

We can access healthy donor whole blood or PBMCs to isolate immune cell populations for evaluating mechanisms of action and functional analysis of drug candidates.

Through our collaborations with hospital partners and working with credible vendors, we implement stringent sample collection protocols to ensure lymphocytes and tumors are processed accordingly. We isolate lymphocyte populations and process tumor tissues for use across various assay platforms.  In addition, we have expertise to characterize (genomic and phenotypic) tumors.

 

Other Tumors

In addition to our proprietary HLA-matched CTL and Tumors and patient-derived samples, we have additional proprietary tumor cell lines for comparative analysis. We also have experience in commercially available cell lines to immune-mediated mechanisms and function by disease.

Visit our Build-a-System page to view the tumor lines we’ve worked with based on indication.

Tumor 005 excised from a “low-risk” primary melanoma of the superficial spreading type. The tumor had brisk lymphocyte infiltration. This line is Mart1/Melan A/gp 100 positive.

Markers Expressed

PD-L1, PD-L2, HVEM, ICOSL, GITRL, CEACAM-1L, CSF-1R

Chemokines Expressed

CCL21, CCL25, and CXCL9

 Short Tandem Repeats (STR) – whole genome sequencing

AMEL-1 ,AMEL-2 ,CSF1PO-1 ,CSF1PO-2, D13S317-1, D13S317-2, D16S539-1, D16S539-2 ,D21S11-1, D21S11-2, D5S818-1, D5S818-2, D7S820-1, D7S820-2, TH01-1, TH01-2, TPOX-1, TPOX-2, vWA-1, vWA-2, D18S51-1, D18S51-2, D19S433-1, D19S433-2, D2S1338-1, D2S1338-2, D3S1358-1, D3S1358-2, D8S1179-1, D8S1179-2, FGA-1

Tumor 006 derived from a male melanoma patient with stage III metastatic melanoma and lymph node involvement.

Markers Expressed

PD-L1, PD-L2, HVEM, OX-40L, CD155, CD112, LAG-3, CD44, CD95 (FasL)

Chemokines

CCL21, CCL25, and CXCL9

 Short Tandem Repeats (STR) (whole exome sequencing)

 AMEL-1 ,AMEL-2, CSF1PO-1, CSF1PO-2, D13S317-1, D13S317-2, D16S539-1, D16S539-2, D21S11-1, D21S11-2, D5S818-1, D5S818-2, D7S820-1, D7S820-2, TH01-1, TH01-2, TPOX-1, TPOX-2, vWA-1, vWA-2, D18S51-1, D18S51-2, D19S433-1, D19S433-2, D2S1338-1, D2S1338-2, D3S1358-1, D3S1358-2, D8S1179-1, D8S1179-2, FGA-1, FGA-2